ES2280972T3 - Preparaciones farmaceuticas combinadas que contienen glutaminasa y antraciclinas o compuestos de platino antineoplasicos para la terapia del cancer. - Google Patents

Preparaciones farmaceuticas combinadas que contienen glutaminasa y antraciclinas o compuestos de platino antineoplasicos para la terapia del cancer. Download PDF

Info

Publication number
ES2280972T3
ES2280972T3 ES04739811T ES04739811T ES2280972T3 ES 2280972 T3 ES2280972 T3 ES 2280972T3 ES 04739811 T ES04739811 T ES 04739811T ES 04739811 T ES04739811 T ES 04739811T ES 2280972 T3 ES2280972 T3 ES 2280972T3
Authority
ES
Spain
Prior art keywords
glutaminase
compound
antineoplastic
activity
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04739811T
Other languages
English (en)
Spanish (es)
Inventor
Frank Leenders
Wenke Seifert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Carolina
Original Assignee
University of South Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of South Carolina filed Critical University of South Carolina
Application granted granted Critical
Publication of ES2280972T3 publication Critical patent/ES2280972T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES04739811T 2003-06-11 2004-06-11 Preparaciones farmaceuticas combinadas que contienen glutaminasa y antraciclinas o compuestos de platino antineoplasicos para la terapia del cancer. Expired - Lifetime ES2280972T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10326821A DE10326821A1 (de) 2003-06-11 2003-06-11 Pharmazeutische Kombinationspräparate zur Krebstherapie
DE10326821 2003-06-11

Publications (1)

Publication Number Publication Date
ES2280972T3 true ES2280972T3 (es) 2007-09-16

Family

ID=33495036

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04739811T Expired - Lifetime ES2280972T3 (es) 2003-06-11 2004-06-11 Preparaciones farmaceuticas combinadas que contienen glutaminasa y antraciclinas o compuestos de platino antineoplasicos para la terapia del cancer.

Country Status (9)

Country Link
US (1) US20060263346A1 (enExample)
EP (1) EP1633394B1 (enExample)
JP (1) JP2006527232A (enExample)
AT (1) ATE350054T1 (enExample)
AU (1) AU2004244755B9 (enExample)
CA (1) CA2528897A1 (enExample)
DE (2) DE10326821A1 (enExample)
ES (1) ES2280972T3 (enExample)
WO (1) WO2004108153A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009536173A (ja) 2006-05-10 2009-10-08 メディカル エンザイムズ アクチエンゲゼルシャフト グルタドン
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
EP2047858A1 (en) * 2007-10-10 2009-04-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Combination products for treating cancer
EP3092235A2 (en) 2014-01-06 2016-11-16 Rhizen Pharmaceuticals S.A. Novel inhibitors of glutaminase

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020094542A1 (en) * 1988-04-15 2002-07-18 Peter Leskovar Drugs and methods for treating cancer
US4955857A (en) * 1988-07-18 1990-09-11 Shettigar Udipi R Multi-enzyme bioreactor therapy for cancer
US5776458A (en) * 1990-12-05 1998-07-07 Pharmacia & Upjohn S.P.A. Anthracycline-conjugates
DE4140003C2 (de) * 1991-12-04 1994-09-29 Joseph Prof Dr Roberts Gentechnisch hergestellte Glutaminase und ihre Verwendung bei der antiviralen und Anti-Krebstherapie
ATE361984T1 (de) * 1992-12-04 2007-06-15 Me Medical Enzymes Ag Gentechnologisch hergestellte glutaminase und ihre verwendung in therapie
DE69332637T2 (de) * 1993-03-04 2003-10-23 Matsushita Electric Industrial Co., Ltd. Kokainderivat,Proteinkonjugat,davon,einen monoklonalen Antikörper produzierende Hybridom-Zellinie, Verfahren zur Herstellung der Hybridom-Zellinie und des monoklonalen Antikörpers
US20020115609A1 (en) * 1997-07-14 2002-08-22 Hayat Onyuksel Materials and methods for making improved micelle compositions
US6200754B1 (en) * 1998-03-19 2001-03-13 Variagenics, Inc. Inhibitors of alternative alleles of genes encoding products that mediate cell response to environmental changes
CA2465949A1 (en) * 2001-11-02 2003-05-15 Dana-Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilities and defective dna repair mechanisms and treatment thereof
WO2003039545A2 (en) * 2001-11-07 2003-05-15 Millennium Pharmaceuticals, Inc. Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers

Also Published As

Publication number Publication date
EP1633394B1 (de) 2007-01-03
WO2004108153A1 (de) 2004-12-16
AU2004244755B9 (en) 2009-12-24
DE502004002561D1 (de) 2007-02-15
AU2004244755B2 (en) 2009-06-25
JP2006527232A (ja) 2006-11-30
US20060263346A1 (en) 2006-11-23
EP1633394A1 (de) 2006-03-15
ATE350054T1 (de) 2007-01-15
DE10326821A1 (de) 2005-01-05
AU2004244755A1 (en) 2004-12-16
CA2528897A1 (en) 2004-12-16

Similar Documents

Publication Publication Date Title
ES2409755T3 (es) Método para Tratar el Cáncer Utilizando un Agente Anticanceroso Combinado
KR102452022B1 (ko) 항종양 알칼로이드를 이용한 병용요법
RU2394581C2 (ru) ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ
US20030096823A1 (en) Method for the treatment of cardiotoxicity induced by antitumor compounds
ES2282400T3 (es) Composiciones antitumorales que contienen derivados de taxano.
ES2848706T3 (es) Terapia de combinación contra el cáncer usando un compuesto azabicíclico
TWI386214B (zh) 包含亞砷酸、其鈉鹽及其衍生物之用於泌尿生殖器癌及其轉移之治療的醫藥組合物
ES2689760T3 (es) Combinación de bortezomib con afuresertib y uso de la misma en el tratamiento de cáncer
JP2009536956A (ja) 抗癌治療法
ES2280972T3 (es) Preparaciones farmaceuticas combinadas que contienen glutaminasa y antraciclinas o compuestos de platino antineoplasicos para la terapia del cancer.
TWI362941B (en) Methods for effecting regression of tumoer mass and size in a metastasized tumor
JP5336466B2 (ja) コレスタノール誘導体の併用用途
JPWO2012147901A1 (ja) 抗癌剤副作用改善用組成物
ES2978336T3 (es) Combinación de un inhibidor de Mcl-1 y midostaurina, usos y composiciones farmacéuticas de la misma
AU2009240908B2 (en) Methods of administering antitumor agent comprising deoxycytidine derivative
TW201249435A (en) Antitumoral combination comprising cabazitaxel and cisplatin
ES2896051T3 (es) Fármaco antitumoral que contiene un complejo de platino antitumoral y un potenciador del efecto antitumoral
US20200375943A1 (en) Cytocidal method of cancer cells selectively in human patients clinically by depletion of l-ascorbic acid, primarily, with its supplementation alternately augmenting its cytocidal effect
ES2289483T3 (es) Procedimiento para el tratamiento del cancer hepatico mediante la administracion intrahepatica de nemorubicina.
ES2806449T3 (es) Fármaco antitumoral que contiene compuesto de taxano y potenciador del efecto antitumoral
ES2534800T3 (es) Derivado de colestanol para uso combinado
JP5480241B2 (ja) コレスタノール誘導体の併用用途
RU2482855C2 (ru) Противоопухолевое средство, включающее производное цитидина и карбоплатин
JP5503528B2 (ja) 癌の処置に寄与する方法および組成物
HK1202419B (en) Combination therapy with a mitotic inhibitor